벨라이트 바이오 ADR(BLTE)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $171.43 (+0.63%), 시가총액 $5.75B, 52주 최저~최고 $56.81 ~ $190.30.
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Bel
벨라이트 바이오 ADR의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
벨라이트 바이오 ADR의 현재 주가는 $171.43 (+0.63%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
벨라이트 바이오 ADR의 시가총액은 약 $5.75B입니다.
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead prod